SHIN NIPPON BIOMEDICAL LABORATORIES (2395) FY2027 Q1

Quick View

Executive Summary

In addition to higher revenue, the Company achieved a return to operating profitability from the loss recorded in the previous year, resulting in a significant earnings increase. Revenue was ¥7.87B (¥6.48B in the previous year, YoY +21.5%), while Operating Income was ¥0.52B, representing a return to profitability from ¥-0.34B in the previous year. Ordinary Income was ¥1.43B (up +177.9%), and Net Income was ¥1.06B (up +308.6%). In addition to higher revenue and earnings in the core CRO Business, non-operating factors such as equity-method investment gains and foreign exchange gains significantly lifted Ordinary Income and Net Income.

Factors Affecting Business Performance

【Revenue】The ¥7.87B increase in revenue (+21.5%) was driven by growth in the core CRO Business, which accounts for 95.8% of total revenue (¥7.54B, +21.9%). The Medipolis Business (¥0.24B, +12.8%) and U.S. Real Estate Business (¥0.05B, +13.7%) also contributed to higher revenue, while the Other Businesses (¥0.11B, -26.0%) recorded a decline.

【Profit and Loss】Operating Income was ¥0.52B, representing a return to profitability from ¥-0.34B in the previous-year period. Operating Income from the CRO Business was ¥1.54B (+100.0%, margin 20.4%), serving as the primary driver for the Company as a whole. The improvement in the SG&A ratio to 44.8% from 52.7% in the previous year, a 7.9pt improvement, allowed the benefit of higher revenue to flow through to earnings. Meanwhile, the Translational Research Business continued to incur a loss of ¥-0.97B, diluting the Company-wide margin, although the loss narrowed slightly year on year (+12.3%). Ordinary Income of ¥1.43B (+177.9%) was significantly boosted by non-operating factors, including ¥0.83B in equity-method investment gains and ¥0.17B in foreign exchange gains. The extraordinary loss of ¥0.03B (loss on disposal of fixed assets, a temporary factor) was immaterial. Net Income was ¥1.06B (+308.6%), supporting the conclusion that the Company achieved higher revenue and earnings.

Segment Analysis

The CRO Business generated revenue of ¥7.54B (+21.9%) and Operating Income of ¥1.54B (+100.0%, margin 20.4%), making it the Company’s earnings source. Both revenue growth and profitability improvement progressed simultaneously. The Translational Research Business recorded revenue of ¥0.06B (+26.9%) and an operating loss of ¥-0.97B, suppressing the Company-wide profit margin as the business remains in the research investment phase. The Medipolis Business posted revenue of ¥0.24B (+12.8%) and Operating Income of ¥0.02B (-51.6%), resulting in lower earnings despite higher revenue. The U.S. Real Estate Business recorded revenue of ¥0.05B (+13.7%) and an operating loss of ¥-0.03B (-20.9%), with the loss expanding. Based on Operating Income, the segment mix is highly concentrated in the CRO Business, creating a structure in which CRO project trends significantly affect overall performance.

Key Financial Indicators

【Profitability】The Operating Margin was 6.6%, improving by 11.8pt from -5.2% in the previous-year period and returning to profitability. The Net Profit Margin was 13.5%, improving by 9.5pt from 4.0% in the previous year. However, non-operating income of ¥1.07B, equivalent to 13.6% of revenue, made a significant contribution to Ordinary Income. In particular, equity-method investment gains of ¥0.83B accounted for 58% of Ordinary Income, which warrants attention.【Cash Flow Quality】Cash and deposits were ¥14.33B, down ¥4.20B (-22.7%) from the end of the previous fiscal year. Against inventories of ¥17.21B and accounts receivable of ¥7.17B, accounts payable were limited to ¥0.26B, indicating that the accumulation of operating assets is affecting the Company’s cash position.【Investment Efficiency】ROE was 2.5%, while BPS was ¥1,002.4, down 3.2% from ¥1,035.76 at the end of the previous fiscal year, as negative comprehensive income during the period weighed on equity.【Financial Soundness】The Equity Ratio was 42.2%, up 1.2pt from 41.0% at the end of the previous fiscal year. However, interest-bearing debt totaled ¥36.86B, comprising ¥19.57B in short-term debt and ¥17.29B in long-term debt. Debt/Capital was 46.6%, with 53.1% of interest-bearing debt concentrated in short-term borrowings, while the quick ratio remained at 58.1%.

Cash Flow Analysis

Cash and deposits were ¥14.33B, down ¥4.20B (-22.7%) from the end of the previous fiscal year. Long-term borrowings were ¥17.29B, down ¥3.84B (-18.2%) from ¥21.12B at the end of the previous fiscal year, suggesting that debt repayments were one factor behind the decline in cash. Meanwhile, inventories increased by ¥2.09B from the end of the previous fiscal year to ¥17.21B, indicating that funds are becoming increasingly tied up in connection with business expansion. Of the current-period Net Income of ¥1.06B, equity-method investment gains of ¥0.83B represent non-cash gains, suggesting that actual cash-generating capacity may be growing more slowly than income statement earnings.

Earnings Quality

The core of recurring earnings power is the CRO Business’s Operating Income of ¥1.54B. However, during the quarter, non-operating income of ¥1.07B, equivalent to 13.6% of revenue, significantly lifted Ordinary Income to ¥1.43B. Equity-method investment gains of ¥0.83B accounted for 58% of Ordinary Income, while foreign exchange gains of ¥0.17B accounted for approximately 12%, indicating a high degree of dependence on non-operating income. Extraordinary income and losses were immaterial, comprising extraordinary income of ¥0.001B and an extraordinary loss of ¥0.03B (loss on disposal of fixed assets), limiting distortion from temporary factors. The difference between Ordinary Income of ¥1.43B and Net Income of ¥1.06B, reflecting an effective tax rate of 24.5%, falls within a reasonable range for corporate taxes. Net Income exceeding Operating Income of ¥0.52B reflects the contribution of non-operating factors; therefore, the sustainability of earnings power on an operating basis should be prioritized in evaluating subsequent periods.

Earnings Forecast and Guidance

Progress against the full-year plan was 20.7% for revenue, 17.4% for Operating Income, 23.9% for Ordinary Income, and 30.3% for Net Income. Using one-quarter (25%) as the benchmark, revenue and Operating Income are somewhat behind schedule, while Ordinary Income and Net Income are ahead. The lead in Ordinary Income and Net Income was driven by non-operating factors such as equity-method investment gains and foreign exchange gains, contrasting with the modest growth assumption in the full-year plan of Ordinary Income of ¥6.00B (YoY +2.9%). The delay in Operating Income progress appears to reflect the continued losses in the Translational Research Business, and achieving the full-year target of ¥3.00B will require margin expansion over the remaining 3 quarters. Although the earnings forecast was revised during the quarter, the dividend forecast was unchanged, and the annual dividend of ¥50.00 remains intact.

Shareholder Returns

The annual dividend forecast is ¥50.00, representing a planned increase of ¥30 from the previous fiscal year’s actual dividend of ¥20 (+150%). Based on forecast EPS of ¥84.07, the Payout Ratio is approximately 59.5%, indicating an increased emphasis on shareholder returns during the earnings expansion phase. No data on share repurchases is available, and shareholder returns are centered on dividends. Given the level of short-term borrowings and the decline in cash and deposits (-22.7%), achievement of the full-year plan will be an important prerequisite for the dividend to be delivered.

Risk Factors

1. Business Segment Concentration Risk: The CRO Business accounts for 95.8% of revenue and almost all Operating Income, creating a structure in which project trends, utilization rates, and pricing fluctuations in this business significantly affect overall performance.

2. Dependence on Non-Operating Earnings: Equity-method investment gains of ¥0.83B (58%) and foreign exchange gains of ¥0.17B (12%) together account for approximately 70% of Ordinary Income of ¥1.43B, making earnings levels susceptible to market and foreign exchange fluctuations.

3. Concentration of Short-Term Funding: Of the ¥36.86B in interest-bearing debt, 53.1% consists of short-term borrowings. Cash and deposits declined 22.7% from the end of the previous fiscal year, and the quick ratio was 58.1%, a level requiring attention with respect to funding flexibility.

Industry Benchmark (Reference, Compiled by the Company)

Industry Benchmark (it_telecom)

Profitability and Returns

The Operating Margin is slightly below the industry median, while the Net Profit Margin exceeds the industry median partly due to the contribution of non-operating factors.

Growth and Capital Efficiency

The Revenue Growth Rate significantly exceeds the industry median, indicating a high growth rate within the industry.

Source: Compiled by the Company

Key Takeaways from the Earnings Results

1. Operating results returned to profitability, improving from ¥-0.34B in the previous year to ¥0.52B, while the SG&A ratio improved from 52.7% in the previous year to 44.8%. The emergence of operating leverage through higher CRO Business revenue and cost absorption has been confirmed, suggesting signs of a structural improvement in profitability.

2. Net Income of ¥1.06B (+308.6%) is highly dependent on non-operating factors, including equity-method investment gains of ¥0.83B and foreign exchange gains of ¥0.17B, with non-operating factors accounting for approximately 70% of Ordinary Income of ¥1.43B. The trend in operating earnings power will be a key focus in assessing sustainability from the next fiscal period onward.

3. A substantial dividend increase is planned, from the previous fiscal year’s actual dividend of ¥20 to ¥50 (+150%), and the dividend forecast remains unchanged. However, the fact that 53.1% of interest-bearing debt is concentrated in short-term borrowings and that cash and deposits have declined 22.7% requires monitoring together with progress against the full-year plan.

Theoretical Share Price (Reference Value)

This is a mechanically calculated reference range based solely on publicly available data using a residual income model (Ohlson-type model with an explicit 5-year fade). It is not a forecast of the market share price or a recommendation of any specific investment action.

Sensitivity: ¥950–¥1,003 at ±1% for the cost of equity, and ¥975–¥976 at ±0.1 for ω.

Notes:

• As forecast ROE is below the cost of equity, the theoretical value is below Book Value Per Share.
• Net assets as of the end of the quarter are used, resulting in a timing gap relative to the full-year forecast.

(Calculation model: Residual Income Model / Interest Rate Reference Month: 2026-07 / This value does not forecast or guarantee the future share price)

---

This report is an earnings analysis document automatically generated by AI through analysis of XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly available earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting professionals as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2027 Q1 was a clear operational recovery quarter, with revenue growth and a return to operating profitability, although earnings remained materially supported by non-operating investment-related income. Revenue increased 21.5% YoY to ¥7.87bn. Operating income improved to ¥0.52bn from a ¥0.34bn operating loss in FY2026 Q1. The operating margin therefore improved by approximately 1,190bp to 6.6% from negative 5.3%. Gross profit rose 31.9% YoY to ¥4.05bn, outpacing revenue growth and lifting the gross margin by approximately 400bp to 51.4%. SG&A expenses increased only 3.4% YoY to ¥3.53bn, demonstrating substantial operating leverage as the revenue base expanded. Ordinary income rose 177.9% YoY to ¥1.43bn, while profit attributable to owners increased 308.6% to ¥1.06bn. Net margin reached 13.5%, exceeding the operating margin because non-operating income of ¥1.07bn was substantial. Equity-method earnings of affiliates were ¥0.83bn and FX gains were ¥0.17bn, together accounting for a large portion of the non-operating uplift. Consequently, the difference between ordinary income and operating income indicates that reported net earnings should not be interpreted as entirely driven by the core CRO operation. Comprehensive income was negative ¥0.12bn despite positive net income, principally reflecting negative valuation differences on securities of ¥1.90bn. The core CRO segment was the principal driver, with segment profit doubling YoY to ¥1.54bn on revenue growth to ¥7.53bn. The Translational Research segment remained loss-making, albeit its segment loss narrowed to ¥0.97bn from ¥1.10bn. The company has revised its full-year forecast, and Q1 progress is 20.7% for revenue, 17.4% for operating income, 23.9% for ordinary income, and 30.4% for profit attributable to owners. The operating-income progress rate is below the standard 25% Q1 pace, whereas profit progress is ahead of that pace due to the concentration of non-operating income in Q1. Balance-sheet liquidity is narrow, with a 101.7% current ratio and 58.1% quick ratio, while 53.1% of interest-bearing debt is short term. The key forward issue is whether CRO profitability can continue to improve sufficiently to support earnings and debt service without relying on equity-method income, FX gains, or working-capital funding.

Profitability Analysis

The reported annualized ROE is 10.1%, decomposed into a 13.5% net profit margin, 0.314x asset turnover, and 2.37x financial leverage. The strongest contributor to the Q1 improvement was the profit-margin recovery: the operating margin turned positive to 6.6% from negative 5.3% a year earlier, while gross margin expanded to 51.4% from approximately 47.4%. This reflected revenue growth of 21.5% combined with SG&A growth of only 3.4%, indicating favorable operating leverage. The CRO business was the core business by operating-income contribution, producing ¥1.54bn of segment profit on ¥7.53bn of revenue, equivalent to an approximately 20.4% segment margin, versus ¥0.77bn and roughly 12.4% a year earlier. By contrast, Translational Research generated only ¥0.06bn of revenue and recorded a ¥0.97bn loss, although this was narrower than the prior-year ¥1.10bn loss. Medipolis contributed ¥0.16bn of segment profit on ¥1.83bn of revenue, for an approximately 9.0% margin, while the US real-estate business reported a ¥0.29bn loss on ¥0.49bn of revenue. The reported 13.5% net margin is stronger than the 6.6% EBIT margin because non-operating income totaled ¥1.07bn, or 13.6% of revenue. Equity-method earnings of ¥0.83bn represented about 77% of non-operating income, and FX gains of ¥0.17bn equaled 33.1% of operating income; therefore, core operating profitability remains meaningfully below headline net profitability. The 2.703x interest-burden ratio is mechanically elevated because profit before tax exceeded EBIT as a result of non-operating income; it should not be read as evidence of unusually low debt burden. Interest coverage was 4.87x, slightly below the 5x strong-coverage benchmark but above the 3x concern threshold. The effective tax rate of 24.5% and tax burden of 0.755 were normal, supporting conversion of pre-tax income to net income. Capital efficiency remains a concern: the quality alert indicates ROIC of 2.4%, below the 5% warning threshold, suggesting the large asset base is not yet producing returns commensurate with the improvement in quarterly earnings.

Growth Assessment

Revenue growth was broad enough to be led decisively by the CRO business, where external sales increased 22.0% YoY to ¥7.53bn. CRO segment profit increased 100.0% YoY to ¥1.54bn, materially faster than sales, demonstrating high incremental margins and improved utilization or project mix. The group-level gross-profit increase of 31.9% also supports the view that the sales expansion was profitable rather than purely volume-driven. Medipolis revenue grew 8.0% YoY to ¥1.83bn, though segment profit declined 51.6% YoY to ¥0.16bn, pointing to margin pressure. The Translational Research loss narrowed by ¥0.14bn YoY, but the segment remains a significant drag on consolidated earnings. US real-estate revenue increased 13.7% YoY to ¥0.49bn, while its loss widened to ¥0.29bn from ¥0.24bn. Full-year guidance calls for revenue of ¥38.0bn, operating income of ¥3.0bn, ordinary income of ¥6.0bn, and profit attributable to owners of ¥3.5bn. Q1 revenue progress of 20.7% and operating-income progress of 17.4% are respectively 4.3 percentage points and 7.6 percentage points below the standard 25% Q1 pace, implying that management expects a more second-half-weighted operating-profit contribution. Ordinary-income progress of 23.9% is near the standard pace, while profit progress of 30.4% is above it. The disparity between operating and net-income progress reinforces the importance of non-operating contributors, particularly equity-method earnings and FX gains, in the Q1 outcome. Forecast growth assumptions remain constructive, with full-year revenue, operating income, and ordinary income expected to rise 16.8%, 13.0%, and 2.9%, respectively. The lower guided operating-profit growth than revenue growth also implies some normalization in incremental margins after the sharp Q1 recovery.

Financial Health

Liquidity is tight rather than impaired. The current ratio is 101.7%, only modestly above 1.0x, and the quick ratio is 58.1%, indicating that current-liability coverage depends materially on inventories and other non-cash current assets. Working capital was positive at ¥0.65bn, but this is a limited buffer against funding volatility. Current liabilities totaled ¥39.49bn, including ¥19.57bn of short-term loans, while cash and deposits were ¥14.33bn. Cash therefore covered only 0.73x short-term debt, creating a meaningful refinancing requirement. The short-term debt ratio of 53.1% exceeds the 40% quality-alert threshold; the root cause is the concentration of ¥19.57bn of borrowings in short-term loans relative to total interest-bearing debt of ¥36.86bn. This maturity profile is more aggressive than a fully matched long-term capital structure, especially given substantial investments in property, plant and equipment of ¥36.64bn and inventories of ¥17.21bn. The impact is that continued access to bank funding and successful rollover of short-term facilities are important to maintain liquidity. Total debt-to-equity was 1.37x, below the 2.0x aggressive-leverage warning threshold but above a conservative 1.0x level. Debt represented 46.6% of capital, above the 40% investment-grade reference point but below the 60% concern threshold. Long-term loans decreased ¥3.84bn YoY to ¥17.29bn, while short-term loans decreased only ¥0.10bn, increasing reliance on shorter maturities. Accounts payable declined 35.2% YoY to ¥0.26bn, reducing spontaneous supplier financing and modestly increasing the importance of other operating-liability funding. Advances received increased to ¥16.73bn from ¥14.71bn, providing an important operating funding source. Goodwill was ¥1.75bn, equal to only 4.1% of equity and 1.7% of assets, so balance-sheet value is not materially dependent on goodwill retention. Lease obligations of ¥0.73bn are an additional fixed financial commitment, though modest relative to total debt.

Notable B/S Changes

Accounts payable: -¥0.14bn (-35.2%) to ¥0.26bn — lower supplier financing contributes to the extended cash conversion cycle and reduces liquidity support from operating liabilities. Cash and deposits: -¥4.20bn (-22.7%) to ¥14.33bn — reduced cash reserves leave cash covering only 0.73x of short-term debt. Valuation difference on securities: -¥1.90bn (-24.0%) to ¥6.01bn — market-value movements in the securities portfolio drove negative comprehensive income and remain a source of equity volatility. Foreign currency translation adjustment: +¥0.72bn (+128.3%) to ¥1.28bn — overseas asset and liability translation materially affects accumulated other comprehensive income, underscoring currency sensitivity. Non-controlling interests: +¥0.17bn (+45.0%) to ¥0.53bn — the increased minority-interest balance modestly reduces the share of future subsidiary earnings attributable to owners of the parent.

Cash Flow Quality

The quarterly operating cash-flow and investing cash-flow figures are not included in the reported financial data, so cash conversion, free-cash-flow coverage, and OCF-to-net-income cannot be quantified. Earnings quality can nevertheless be assessed through the composition of profit and balance-sheet operating-capital indicators. Net income of ¥1.06bn exceeded operating income of ¥0.52bn because non-operating income was ¥1.07bn, principally ¥0.83bn of equity-method earnings and ¥0.17bn of FX gains. This makes cash realization of reported earnings particularly important, because equity-method income and foreign-exchange gains do not necessarily translate into immediate operating cash receipts. The quality alert for DSO of 83 days, above the 60-day threshold, indicates relatively slow receivables collection and creates a risk that revenue conversion to cash lags accounting recognition. Trade receivables were ¥7.17bn, equivalent to 7.2% of total assets. The DIO alert of 411 days is substantially above both the 90-day and 60-day warning thresholds. Inventories increased ¥2.09bn YoY to ¥17.21bn and represented 17.2% of total assets, tying up a significant amount of capital. While inventory may partly reflect the company's diversified operations, including non-CRO activities, this level is high for the consolidated revenue base and requires evidence of turnover and valuation discipline. The reported cash conversion cycle of 488 days, far above the 120-day alert threshold, combines slow collection and very high inventory intensity with limited trade-payables funding. The decline in accounts payable to ¥0.26bn from ¥0.41bn further reduces supplier-financing support. These factors are potential working-capital risks rather than proof of manipulation, but they raise the required standard of evidence for sustainable free-cash-flow generation.

Dividend Sustainability

The full-year dividend forecast is ¥50.0 per share, compared with forecast EPS of ¥84.07. This implies a dividend payout ratio of approximately 59.5%, which is within the 60% sustainability benchmark but leaves limited headroom if earnings fall below plan. Based on 41.63 million shares outstanding, the indicated annual cash dividend is approximately ¥2.08bn. This compares with forecast profit attributable to owners of ¥3.50bn, again implying coverage of approximately 1.68x by forecast earnings. Q1 EPS of ¥25.55 represents 30.4% of the full-year EPS forecast, which is ahead of a simple 25% seasonal pace. However, Q1 net earnings benefited from equity-method income and FX gains, so the durability of dividend coverage depends on operating-profit delivery through the remainder of the fiscal year. The relatively thin liquidity buffer, 0.73x cash-to-short-term-debt ratio, and elevated working-capital cycle make cash generation more important than accounting earnings in assessing distributions. No share-buyback program is indicated; accordingly, the relevant distribution metric is the dividend payout ratio rather than a total return ratio. The stated ¥50 DPS appears earnings-covered under current guidance, but dividend capacity remains sensitive to refinancing conditions, working-capital absorption, and the conversion of affiliate-related earnings into cash.

Risk Assessment

Business risks include CRO execution risk: the core CRO segment generates the majority of revenue and segment profit; any clinical-development project delays, customer budget reductions, cancellations, or capacity-utilization deterioration would disproportionately affect consolidated earnings., Translational Research profitability risk: the segment remained loss-making at ¥0.97bn in Q1 despite a ¥0.14bn YoY improvement, and continued losses could offset CRO earnings., US real-estate and Medipolis volatility: the US real-estate segment widened its loss to ¥0.29bn, while Medipolis profit declined 51.6% YoY, limiting diversification benefits., FX exposure: FX gains of ¥0.17bn equaled 33.1% of operating income. The root cause is exposure from overseas operations and/or foreign-currency financial assets. This can be normal for an internationally active CRO group, but the Q1 contribution is large enough that currency reversal would reduce ordinary income and net income., Industry-specific CRO risk: regulatory changes, trial-protocol complexity, investigator-site capacity constraints, and competition for specialized scientific personnel can affect project timing, pricing, and delivery margins..

Financial risks include Refinancing risk: 53.1% of interest-bearing debt is short term, above the 40% quality-alert threshold. With ¥19.57bn of short-term loans and only ¥14.33bn of cash, the company depends on facility renewal and operating cash inflows., Liquidity risk: the current ratio is only 101.7% and the quick ratio is 58.1%, leaving limited liquid-asset coverage after excluding inventories., Working-capital risk: DSO of 83 days, DIO of 411 days, and a 488-day cash conversion cycle indicate substantial capital tied up in operations. The impact is weaker cash flexibility for debt repayment, investment, and dividends., Interest-service risk: interest coverage of 4.87x is acceptable but below the 5x strong-coverage benchmark. Rising funding costs or a reduction in operating profit would narrow coverage., Securities valuation risk: investment securities were ¥19.08bn, or 19.0% of assets, and negative valuation differences on securities contributed to negative comprehensive income..

Key concerns include The annualized ROE of 10.1% is acceptable, but the ROIC quality alert of 2.4% is below the 5% warning threshold. The root cause is low operating return relative to the large debt-funded asset base. The impact is that value creation and deleveraging capacity depend on a sustained improvement in core operating profitability., Headline net margin of 13.5% overstates underlying operating profitability because the EBIT margin was 6.6% and non-operating income exceeded operating income., Equity-method earnings of ¥0.83bn represented a major component of Q1 profit; affiliate performance volatility therefore remains material., Negative comprehensive income of ¥0.12bn despite ¥1.06bn of net income indicates that market-value movements in securities can reduce book equity., The combination of high inventory days and low quick liquidity means that balance-sheet flexibility may be weaker than the positive current ratio alone suggests..

Investment Implications

Key takeaways include Q1 demonstrated a strong recovery in the core CRO business: revenue increased 22.0% YoY and segment profit doubled to ¥1.54bn., Group operating margin recovered to 6.6%, supported by gross-margin expansion and restrained SG&A growth., Reported net income was enhanced by ¥0.83bn of equity-method earnings and ¥0.17bn of FX gains, requiring separation of operating and non-operating earnings drivers., Short-term funding concentration, high inventory days, and a 488-day cash conversion cycle are the principal balance-sheet and cash-discipline issues., The forecast ¥50 DPS implies an approximately 59.5% payout ratio, near the upper end of the stated sustainability benchmark..

Metrics to watch include CRO segment revenue growth, segment margin, and operating-profit conversion, Translational Research segment-loss trajectory, Equity-method earnings and the underlying performance of affiliates, FX gains/losses relative to operating income, Short-term loan balance, cash-to-short-term-debt ratio, and refinancing terms, DSO, inventory balance, DIO, and cash conversion cycle, Operating cash flow and free cash flow relative to net income and dividends, ROIC progression from the reported 2.4% level.

Regarding relative positioning, The company combines a profitable and improving CRO core with diversified but lower-return adjacent operations. Its gross margin and Q1 operating leverage are constructive, but its 6.6% operating margin remains below the 8-15% good benchmark, while ROIC of 2.4%, elevated working-capital intensity, and short-term debt reliance reduce the quality of its relative financial profile.